InflaRx Launches $150M Underwritten Offering to Fund Pipeline and Extend Runway

summarizeSummary

InflaRx N.V. filed a prospectus supplement for a $150 million underwritten public offering of 75 million ordinary shares at $2.00 per share, significantly increasing its cash runway through 2029.

check_boxKey Events

• Launches $150 Million Public Offering

  InflaRx N.V. is conducting an underwritten public offering to sell 75 million ordinary shares at a price of $2.00 per share, aiming to raise $150 million in gross proceeds.

• Significant Share Dilution

  The offering is highly dilutive, as the 75 million new shares represent over 100% of the 72.3 million ordinary shares outstanding as of March 31, 2026.

• Extends Cash Runway Through 2029

  The net proceeds from the offering are intended to fund pipeline activities and general corporate purposes, extending the company's liquidity through 2029.

• Addresses Critical Liquidity Needs

  This capital raise is critical, following a Q1 2026 financial report earlier today that included a material warning and projected liquidity only into 2027, making the financing essential for continued operations.

auto_awesomeAnalysis

This 424B5 filing formalizes a substantial $150 million underwritten public offering, which was previously announced via news. The offering involves the sale of 75 million ordinary shares at $2.00 per share. While the offering price represents a discount to today's market price of $2.49, it is a slight premium to the last reported sale price of $1.97 on May 5, 2026. The offering is highly dilutive, effectively more than doubling the company's outstanding shares and representing a significant portion of its market capitalization. However, this capital infusion is critical for InflaRx, extending its cash runway through 2029 and enabling the advancement of its izicopan pipeline. This financing is particularly crucial following a Q1 2026 financial report earlier today that included a material warning and projected liquidity only into 2027, making this raise essential for continued operations and strategic development, despite the substantial dilution for existing shareholders.